Replay available

Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call

Roivant Sciences Ltd. (NASDAQ: ROIV) Q2 2025 earnings conference call, held 2025-11-10. Replay captured from the company's public earnings webcast.

Mon, November 10, 2025 at 8:00 AMendedReplay
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Stephanie Lee

Investor Relations

Matt Klein

CEO

Dave Rissinger

Analyst, Learing Partners

Brian Cheng

Analyst, JP Morgan

Samantha Semenkov

Analyst, CTEK

Ron Webber

Analyst, TD Cowen

Corinne Johnson

Analyst, Goldman Sachs

Douglas Sutwood

Analyst, H.C. Wainwright

Thomas Smith

Analyst, Learing Partners

Brandon Frith

Analyst, Wolfe Research

Sam Sliske

Analyst, LifeSci Capital

Replay transcript excerpt

Good day. Thank you for standing by. Welcome to the Roy Vance Second Quarter 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. Please note that today's conference is being recorded. I will now hand the conference over to your first speaker, Stephanie Lee. You may begin. Good morning, and thanks for joining today's call to review Royvan's financial results for the second quarter ended September 30th, 2025. I'm Stephanie Lee with Royvan. Presenting today, we have Matt Klein, CEO of Royvan. For those dialing in via conference call, you can find the slides being presented today, as well as the press release announcing these updates on our IR website at www.investor.royvan.com. We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we will be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we filed with the FPC for more information regarding these forward-looking statements and related risks and uncertainty. And with that, I'll turn it over to Matt. Thank you, Steph, and good morning, everybody, and thank you for listening. I appreciate all your dialing in. say, not at all a quiet quarter for us in that we put out both the Graves data and obviously the Phase 3 data for Brebsit, Niven, and DM. So just a tremendous moment of transformation for the business, but a relatively quiet earnings call as we're looking forward to getting everybody together in December for a more ful...

More from Roivant Sciences Ltd.